Source:http://linkedlifedata.com/resource/pubmed/id/18064332
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2007-12-7
|
| pubmed:abstractText |
Low-response to the P2Y12 adenosine diphosphate (ADP)-receptor antagonist clopidogrel was suggested to correspond to a higher incidence of stent thrombosis (ST). This prospective observational study assessed the capability of two platelet function assays, e.g. direct measurement of the phosphorylation status of vasodilator-stimulated phosphoprotein (VASP) and ADP-induced platelet aggregation for definition of the individual risk to develop ST. Ninety-nine patients with an elevated high risk to develop ST were enrolled. All patients received a dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel during an observation period of six months. Flow cytometry of VASP phosphorylation and densitometrically-determined measurement of ADP-induced platelet aggregation was performed 72-96 hours after stent implantation. These data were related to angiographically confirmed ST. Nine patients suffered from angiographically confirmed ST (9.1%). The meanVASP-platelet reactivity indices (VASP-PRI) and values for ADP-induced platelet aggregation in the ST group were significantly higher (60.8 +/- 13.0 and 60.9 +/- 13.1, respectively) compared to patients without ST (41.3 +/- 14.0 and 50.8 +/- 14.4, P < 0.001 vs. 0.048, respectively). There was a fair correlation between both methods using non-linear regression analysis (r = 0.332). In a multivariate analysis, VASP was the only independent predictor of ST and was superior to previously identified angiographic parameters. Receiver- operator characteristic (ROC) curve analysis revealed a cut-off value for VASP-PRI of <48% to be associated with low risk of ST. In conclusion, determination of VASP phosphorylation is superior to conventional platelet aggregometry and angiographic parameters for assessing the risk of ST. Patients with a VASP-PRI >48% seem to have a significantly increased risk.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Diphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/Microfilament Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Ticlopidine,
http://linkedlifedata.com/resource/pubmed/chemical/clopidogrel,
http://linkedlifedata.com/resource/pubmed/chemical/vasodilator-stimulated...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
98
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1329-34
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:18064332-Adenosine Diphosphate,
pubmed-meshheading:18064332-Aged,
pubmed-meshheading:18064332-Angioplasty, Balloon, Coronary,
pubmed-meshheading:18064332-Aspirin,
pubmed-meshheading:18064332-Cell Adhesion Molecules,
pubmed-meshheading:18064332-Coronary Angiography,
pubmed-meshheading:18064332-Drug Therapy, Combination,
pubmed-meshheading:18064332-Female,
pubmed-meshheading:18064332-Flow Cytometry,
pubmed-meshheading:18064332-Humans,
pubmed-meshheading:18064332-Male,
pubmed-meshheading:18064332-Microfilament Proteins,
pubmed-meshheading:18064332-Middle Aged,
pubmed-meshheading:18064332-Phosphoproteins,
pubmed-meshheading:18064332-Phosphorylation,
pubmed-meshheading:18064332-Platelet Aggregation,
pubmed-meshheading:18064332-Platelet Aggregation Inhibitors,
pubmed-meshheading:18064332-Platelet Function Tests,
pubmed-meshheading:18064332-Predictive Value of Tests,
pubmed-meshheading:18064332-Prospective Studies,
pubmed-meshheading:18064332-ROC Curve,
pubmed-meshheading:18064332-Reproducibility of Results,
pubmed-meshheading:18064332-Research Design,
pubmed-meshheading:18064332-Risk Assessment,
pubmed-meshheading:18064332-Risk Factors,
pubmed-meshheading:18064332-Sensitivity and Specificity,
pubmed-meshheading:18064332-Stents,
pubmed-meshheading:18064332-Thrombosis,
pubmed-meshheading:18064332-Ticlopidine,
pubmed-meshheading:18064332-Time Factors,
pubmed-meshheading:18064332-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
|
| pubmed:affiliation |
Department of Cardiology, University Hospital Aachen, Pauwelsstr. 30, 52074 Aachen, Germany. ruediger.blindt@post.rwth-aachen.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|